ECSP21053474A - Vectores de orthopoxvirus modificados - Google Patents
Vectores de orthopoxvirus modificadosInfo
- Publication number
- ECSP21053474A ECSP21053474A ECSENADI202153474A ECDI202153474A ECSP21053474A EC SP21053474 A ECSP21053474 A EC SP21053474A EC SENADI202153474 A ECSENADI202153474 A EC SENADI202153474A EC DI202153474 A ECDI202153474 A EC DI202153474A EC SP21053474 A ECSP21053474 A EC SP21053474A
- Authority
- EC
- Ecuador
- Prior art keywords
- modified orthopoxvirus
- vectors
- orthopoxvirus vectors
- modified
- adaptability
- Prior art date
Links
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
- C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
- C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
- C12N15/86—Viral vectors
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/76—Viruses; Subviral particles; Bacteriophages
- A61K35/768—Oncolytic viruses not provided for in groups A61K35/761 - A61K35/766
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/3955—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against proteinaceous materials, e.g. enzymes, hormones, lymphokines
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/52—Cytokines; Lymphokines; Interferons
- C07K14/54—Interleukins [IL]
- C07K14/5434—IL-12
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
- C07K16/18—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans
- C07K16/28—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
- C07K16/2803—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
- C07K16/2818—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily against CD28 or CD152
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N7/00—Viruses; Bacteriophages; Compositions thereof; Preparation or purification thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24121—Viruses as such, e.g. new isolates, mutants or their genomic sequences
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24122—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24132—Use of virus as therapeutic agent, other than vaccine, e.g. as cytolytic agent
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2710/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA dsDNA viruses
- C12N2710/00011—Details
- C12N2710/24011—Poxviridae
- C12N2710/24111—Orthopoxvirus, e.g. vaccinia virus, variola
- C12N2710/24141—Use of virus, viral particle or viral elements as a vector
- C12N2710/24143—Use of virus, viral particle or viral elements as a vector viral genome or elements thereof as genetic vector
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Genetics & Genomics (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Zoology (AREA)
- Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Biophysics (AREA)
- Molecular Biology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Virology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- General Engineering & Computer Science (AREA)
- Biotechnology (AREA)
- Biomedical Technology (AREA)
- Veterinary Medicine (AREA)
- Pharmacology & Pharmacy (AREA)
- Public Health (AREA)
- Animal Behavior & Ethology (AREA)
- Toxicology (AREA)
- Gastroenterology & Hepatology (AREA)
- Epidemiology (AREA)
- Mycology (AREA)
- Plant Pathology (AREA)
- Physics & Mathematics (AREA)
- Oncology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Endocrinology (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La solicitud se refiere a vectores de orthopoxvirus modificados, así como a métodos para utilizar los mismos para el tratamiento de diversos cánceres. La solicitud provee vectores de orthopoxvirus modificados que exhiben varias actividades terapéuticas beneficiosas, incluyendo aumentadas actividad oncolítica, dispersión de la infección, evasión inmune, persistencia tumoral, capacidad de incorporación de secuencias de ADN exógenas, adaptabilidad para fabricación a gran escala y seguridad.
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201862784372P | 2018-12-21 | 2018-12-21 | |
US201962872699P | 2019-07-10 | 2019-07-10 | |
US201962930524P | 2019-11-04 | 2019-11-04 |
Publications (1)
Publication Number | Publication Date |
---|---|
ECSP21053474A true ECSP21053474A (es) | 2021-11-18 |
Family
ID=71100021
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
ECSENADI202153474A ECSP21053474A (es) | 2018-12-21 | 2021-07-20 | Vectores de orthopoxvirus modificados |
Country Status (18)
Country | Link |
---|---|
US (2) | US20220056480A1 (es) |
EP (2) | EP3898997A4 (es) |
JP (2) | JP2022516006A (es) |
KR (2) | KR20210132002A (es) |
CN (2) | CN113661246A (es) |
AU (2) | AU2019410148A1 (es) |
BR (2) | BR112021012078A2 (es) |
CA (2) | CA3124301A1 (es) |
CL (1) | CL2021001646A1 (es) |
CO (1) | CO2021009354A2 (es) |
EC (1) | ECSP21053474A (es) |
IL (2) | IL284180A (es) |
MX (2) | MX2021007439A (es) |
PE (1) | PE20212307A1 (es) |
PH (1) | PH12021551436A1 (es) |
SG (1) | SG11202106460XA (es) |
TW (1) | TW202039851A (es) |
WO (2) | WO2020124274A1 (es) |
Families Citing this family (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US11802292B2 (en) | 2018-01-05 | 2023-10-31 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
US20230002465A1 (en) * | 2019-11-20 | 2023-01-05 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Vaccinia viruses and methods for using vaccinia viruses |
WO2023106839A1 (ko) * | 2021-12-07 | 2023-06-15 | 재단법인 아산사회복지재단 | Il-12를 발현하는 재조합 백시니아 바이러스 및 이의 용도 |
WO2023135313A1 (en) * | 2022-01-17 | 2023-07-20 | Nouscom Ag | Recombinant orthopox viral vector encoding immunostimulatory proteins for cancer treatment |
WO2023238106A1 (en) * | 2022-06-10 | 2023-12-14 | Transgene | Recombinant virus expressing interleukin-12 |
WO2024023740A1 (en) * | 2022-07-27 | 2024-02-01 | Astrazeneca Ab | Combinations of recombinant virus expressing interleukin-12 with pd-1/pd-l1 inhibitors |
Family Cites Families (6)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
ES2444699T3 (es) * | 2002-08-12 | 2014-02-26 | Jennerex, Inc. | Virus vaccinia para uso en el tratamiento del cáncer |
US20040247578A1 (en) * | 2002-10-15 | 2004-12-09 | University Of Pittsburgh Of Commonwealth System Of Higher Education | Methods and reagents for inducing immunity |
CA2705869C (en) * | 2007-11-19 | 2012-10-30 | Philippe Erbs | Poxviral oncolytic vectors |
CA2921041C (en) * | 2013-08-22 | 2023-10-31 | University Of Pittsburgh - Of The Commonwealth System Of Higher Education | Immuno-oncolytic therapies |
HUE045108T2 (hu) * | 2014-07-16 | 2019-12-30 | Transgene Sa | Onkolitikus vírus immunellenõrzõpont-modulátorok expresszálására |
US11802292B2 (en) * | 2018-01-05 | 2023-10-31 | Ottawa Hospital Research Institute | Modified orthopoxvirus vectors |
-
2019
- 2019-12-20 AU AU2019410148A patent/AU2019410148A1/en active Pending
- 2019-12-20 KR KR1020217022871A patent/KR20210132002A/ko unknown
- 2019-12-20 CA CA3124301A patent/CA3124301A1/en active Pending
- 2019-12-20 CN CN201980092788.4A patent/CN113661246A/zh active Pending
- 2019-12-20 PE PE2021000922A patent/PE20212307A1/es unknown
- 2019-12-20 JP JP2021535833A patent/JP2022516006A/ja active Pending
- 2019-12-20 US US17/415,575 patent/US20220056480A1/en active Pending
- 2019-12-20 TW TW108147116A patent/TW202039851A/zh unknown
- 2019-12-20 MX MX2021007439A patent/MX2021007439A/es unknown
- 2019-12-20 MX MX2021007438A patent/MX2021007438A/es unknown
- 2019-12-20 JP JP2021535804A patent/JP2022514420A/ja active Pending
- 2019-12-20 CA CA3124287A patent/CA3124287A1/en active Pending
- 2019-12-20 KR KR1020217022872A patent/KR20210132003A/ko unknown
- 2019-12-20 US US17/415,606 patent/US20220380799A1/en active Pending
- 2019-12-20 EP EP19898487.4A patent/EP3898997A4/en active Pending
- 2019-12-20 WO PCT/CA2019/051899 patent/WO2020124274A1/en unknown
- 2019-12-20 WO PCT/CA2019/051898 patent/WO2020124273A1/en unknown
- 2019-12-20 EP EP19899693.6A patent/EP3898998A4/en active Pending
- 2019-12-20 AU AU2019404639A patent/AU2019404639A1/en active Pending
- 2019-12-20 BR BR112021012078-5A patent/BR112021012078A2/pt not_active Application Discontinuation
- 2019-12-20 BR BR112021011730-0A patent/BR112021011730A2/pt not_active Application Discontinuation
- 2019-12-20 SG SG11202106460XA patent/SG11202106460XA/en unknown
- 2019-12-20 CN CN201980091966.1A patent/CN113454231A/zh active Pending
-
2021
- 2021-06-17 PH PH12021551436A patent/PH12021551436A1/en unknown
- 2021-06-18 CL CL2021001646A patent/CL2021001646A1/es unknown
- 2021-06-19 IL IL284180A patent/IL284180A/en unknown
- 2021-06-20 IL IL284188A patent/IL284188A/en unknown
- 2021-07-16 CO CONC2021/0009354A patent/CO2021009354A2/es unknown
- 2021-07-20 EC ECSENADI202153474A patent/ECSP21053474A/es unknown
Also Published As
Publication number | Publication date |
---|---|
KR20210132003A (ko) | 2021-11-03 |
AU2019410148A1 (en) | 2021-08-12 |
CL2021001646A1 (es) | 2022-02-18 |
CN113454231A (zh) | 2021-09-28 |
MX2021007439A (es) | 2021-08-05 |
WO2020124274A1 (en) | 2020-06-25 |
CA3124301A1 (en) | 2020-06-25 |
EP3898998A4 (en) | 2022-10-05 |
EP3898997A1 (en) | 2021-10-27 |
CA3124287A1 (en) | 2020-06-25 |
SG11202106460XA (en) | 2021-07-29 |
MX2021007438A (es) | 2021-09-21 |
AU2019404639A1 (en) | 2021-08-12 |
BR112021011730A2 (pt) | 2021-08-31 |
BR112021012078A2 (pt) | 2021-08-31 |
JP2022516006A (ja) | 2022-02-24 |
KR20210132002A (ko) | 2021-11-03 |
PH12021551436A1 (en) | 2021-12-06 |
IL284180A (en) | 2021-08-31 |
WO2020124273A1 (en) | 2020-06-25 |
EP3898998A1 (en) | 2021-10-27 |
JP2022514420A (ja) | 2022-02-10 |
PE20212307A1 (es) | 2021-12-10 |
US20220380799A1 (en) | 2022-12-01 |
TW202039851A (zh) | 2020-11-01 |
IL284188A (en) | 2021-08-31 |
US20220056480A1 (en) | 2022-02-24 |
CO2021009354A2 (es) | 2021-11-19 |
EP3898997A4 (en) | 2022-11-16 |
CN113661246A (zh) | 2021-11-16 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
ECSP21053474A (es) | Vectores de orthopoxvirus modificados | |
MX2020007011A (es) | Vectores de vaccinia modificados. | |
GT201700200A (es) | Composiciones y métodos para activar la señalización dependiente del "estimulador del gen de interferon" | |
MX2020007010A (es) | Vectores modificados de orthopoxvirus. | |
PH12019502518A1 (en) | Alphavirus neoantigen vectors | |
UY37563A (es) | Aislados de bacillus y usos de los mismos | |
MY194058A (en) | Cyclic dinucleotides for treating conditions associated with sting activity such as cancer | |
CL2021000216A1 (es) | Compuestos 1h-pyrazolo [4,3-d]pirimidina como agonistas del receptor 7 tipo toll (tlr7) y métodos y usos de los mismos | |
BR112017024384A2 (pt) | bactérias modificadas para reduzir hiperfenilalaninemia | |
CO2020010956A2 (es) | Composiciones y métodos para el tratamiento del cáncer y de trastornos inmunitarios usando bacterias de veillonella | |
AR113881A1 (es) | Composiciones y métodos para el tratamiento de desórdenes inmunes usando la cepa blautia | |
EA201991214A1 (ru) | Антитела против pd-1 и их композиции | |
MX2023001527A (es) | Compuestos con actividad inductora de ferroptosis y metodos de uso de estos. | |
SG10201811841UA (en) | Methods of treating cancer using tigit inhibitors and anti-cancer agents | |
BR122021000068A8 (pt) | Composições e usos em métodos para estimular a eficácia de imunoterapia celular adotiva | |
MX2018004600A (es) | Celulas aniquiladoras naturales y células ilc3 y usos de las mismas. | |
GT201700025A (es) | Inhibidores de la proteína quinasa c y métodos de su uso | |
CY1124761T1 (el) | Ρυθμιστες της δραστικοτητας του συμπληρωματος | |
BR112017010761A2 (pt) | tratamento de doenças associadas à ativação de célula estrelada hepática com o uso de terapias de redução de amônia | |
MX2020001637A (es) | Agentes de union a cd96 como inmunomoduladores. | |
BR112017021700A2 (pt) | composições terapêuticas e métodos de uso para o tratamento do câncer | |
MY175423A (en) | Microorganism having improved ability to produce l-lysine and method for producing l-lysine using same | |
WO2015170158A8 (en) | Therapy for use in the treatment of tumors, acquired immunodeficiency syndrome and leukemias by dual immune biostimulation | |
CO6290694A2 (es) | Paramyxovirus eficaz como antitumoral | |
AR117470A1 (es) | Vectores de orthopoxvirus modificados |